Europlasma S.A. Plummets 27.6% as Waste Management Stock Hits New Lows

Europlasma S.A. (1EZ0.F) crashed 27.6% today on XETRA, closing at just €0.0042 per share. The French waste management and plasma technology company has become one of the market’s worst performers, with shares down 99.98% over the past year. Trading volume surged to 95,000 shares, 35% above average, signaling panic selling among investors. The stock now trades far below its 50-day average of €0.0178 and its 200-day average of €1.17987, reflecting a company in severe distress.

Why 1EZ0.F Stock Is Collapsing

Europlasma faces a perfect storm of operational and financial challenges. The company reported a massive net loss of €167.83 per share (TTM) and negative operating cash flow of €75.08 per share. With a market cap of just €8.47 million and 1.84 billion shares outstanding, the stock has become essentially worthless on a per-share basis.

The waste management sector demands strong cash generation and operational efficiency. Europlasma’s current ratio of 0.80 signals liquidity stress, while its debt-to-equity ratio of -0.88 reflects negative shareholder equity. The company burns cash faster than it generates revenue, making survival uncertain without major restructuring or capital injection.

Financial Metrics Paint a Bleak Picture

Revenue per share stands at €159.34 (TTM), but the company loses money on every euro of sales. The net profit margin is -105.3%, meaning Europlasma loses more than one euro for every euro earned. Free cash flow per share is -€86.34, showing the business cannot fund operations from its own cash generation.

Meyka AI rates 1EZ0.F with a grade of B, suggesting a HOLD recommendation. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. However, these grades are not guaranteed and we are not financial advisors. The disconnect between the grade and the stock’s collapse reflects the extreme distress in this micro-cap security.

Technical Breakdown and Market Sentiment

Technical indicators confirm severe downward momentum. The RSI sits at 36.28, indicating oversold conditions, while the Williams %R at -97.33 shows extreme selling pressure. The Stochastic %K at 3.63 signals the stock has hit bottom territory, yet the decline continues.

Track 1EZ0.F on Meyka for real-time updates on this distressed security. Volume patterns show institutional and retail investors alike are exiting positions. The stock’s 52-week range of €0.0042 to €27.50 illustrates the catastrophic collapse from peak valuations, with shares down 99.98% year-to-date.

What Lies Ahead for Europlasma

The company’s survival depends on urgent action. With negative equity and massive cash burn, Europlasma must either secure emergency financing, execute a dramatic operational turnaround, or face potential delisting. The waste management sector offers growth opportunities, but this company has failed to capitalize on them.

Investors should recognize 1EZ0.F as a highly speculative, distressed security. The stock trades on XETRA in EUR and carries extreme risk. Without concrete evidence of a business turnaround, this remains a stock for only the most aggressive speculators willing to accept total loss of capital.

Final Thoughts

Europlasma S.A. (1EZ0.F) represents a cautionary tale of operational failure in the waste management sector. The 27.6% daily crash to €0.0042 reflects years of accumulated losses, negative cash flow, and shareholder value destruction. With a market cap of €8.47 million and negative equity, the company faces an existential crisis. Investors should treat this stock as highly speculative and avoid it unless they have deep conviction in a dramatic turnaround. The technical and fundamental data offer no reason for optimism in the near term.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.